Prognostic Factors in Soft Tissue Sarcoma Patients Treated with Pre- or Postoperative Radiotherapy

Abstract

INTRODUCTION[|]Soft tissue sarcoma (STS) is a very rare, heterogeneous, solid tumor of mesenchymal origin that accounts for about 1% of adult malignancies and 15% of pediatric malignancies. The aim of this study was to analyze the data of STS patients who were treated with surgery and preoperative radiotherapy, postoperative radiotherapy, or chemotherapy between 2010 and 2017 for prognostic factors.[¤]METHODS[|]The study included 22 patients with a diagnosis of any type of STS who were treated at a training and research hospital between 2010 and 2017. Data regarding patient age and sex, histological type of the tumor, tumor size, tumor localization, tumor grade, time of radiotherapy (preoperative or postoperative), prescribed radiation dose, chemotherapy treatment regime, length of follow-up, survival, and recurrence of the tumor were analyzed.[¤]RESULTS[|]A total of 22 patients with a mean age of 60.5+-16.2 years (range: 34–86 years) were included in the study. In all, 54.5% of the group had a high-grade sarcoma. The mean follow-up for all 22 patients was 34.1+-22.4 months (range: 5–98 months), with a median of 28.0 months. The mean overall survival (OS) was 82.3+-8.3 months (range: 66.0–98.6). The 3-year OS rate was 78.4%. The mean recurrence-free survival (RFS) was 72.5+-8.8 months (range: 55.0–89.5 months) and the 3-year RFS rate was 69.3%.[¤]DISCUSSION AND CONCLUSION[|]The OS was lower in the group that received chemotherapy and in cases of larger tumors. Preoperative or postoperative administration of radiotherapy did not have any significant effect on OS or RFS. Studies with larger samples are needed to further define the effects of radiotherapy and chemotherapy on OS and complications.[¤]

Keywords

• pre-/ postoperative radiotherapy
• soft tissue sarcoma; survival rates